ClinPGx Blog (Page 50)

Sign in Subscribe

More issues

Watch the PGx educational video from St Jude's Children's Research Hospital

Protocol investigators and family members of patients from St Jude's Family Advisory Council discuss the PG4KDS pharmacogenetics implementation project in a video - we have added a link to the video on our website under the Outreach tab: "PGEN4Kids Study Information". In the video, Mary Relling

Clopidogrel: indication-specific pharmacogenetics

An article published in the May edition of Clinical Pharmacology & Therapeutics reviews the mixed results seen in different studies for the association between adverse cardiovascular events and the CYP2C19*2 allele in patients taking clopidogrel. The CYP2C19*2 allele confers loss of function of the CYP2C19 enzyme and thus

How Do I Subscribe to the PharmGKB Blog?

There are several ways to view our blog: 1. Click on the rotating box images on our homepage - these link directly to the related blog post for each news item. 2. Click on our "News & Events" tab on the top blue bar on our website. Here

The PharmGKB Knowledge Pyramid

The PharmGKB Knowledge Pyramid (Figure 1) provides users with a visualization of the different types of information found in our knowledge base and, how this information is acquired and integrated together – from the accumulation of gene-drug knowledge at the bottom of the pyramid, to the implementation of pharmacogenomics in the

The Clinical Pharmacogenetics Implementation Consortium (CPIC)

The Clinical Pharmacogenetics Implementation Consortium (CPIC) was established in order to provide drug-dosing guidelines based on an individual’s genotype, if this genetic information is already available. These guidelines are published in Clinical Pharmacology and Therapeutics and summaries of the guidelines can be viewed in the PharmGKB on drug or

Data-driven prediction of drug effects and interactions

Tatonetti, et al. have recently published a database of off-label side effects (named OFFSIDES) and a database of drug-drug interactions (named TWOSIDES), both using data derived from the FDA Adverse Event Reporting Systems (AERS). Using these databases, and validating results in patient Electronic Medical Records, they found an increased risk

Welcome to our newly designed website

Here's some of the things we've changed: * The rotating box displaying news and important information - we will be updating this regularly so keep an eye out! * We have added a "Download Data" button now on the homepage for convenience * "Curators' Favorite

Variation in our genes could increase the risk of kidney damage when treated with an anti-HIV drug

Tenofovir is an anti-HIV drug that works by inhibiting the replication of the HIV virus. Transporter genes encode proteins that are involved in the movement of the drug in and out of cells in the body, and the eventual elimination of the drug from the body. Clearance and elimination of